跳至主要内容
临床试验/EUCTR2005-002643-89-IT
EUCTR2005-002643-89-IT进行中(未招募)不适用

Double-blind study to compare the efficacy of palonosetron with or without the use of dexamethasone on days 2 and 3, in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy MEC given to female patients with breast cancer

HELSINN HEALTHCARE SA0 个研究点目标入组 300 人开始时间: 2007年1月18日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Patients that meet all of the following criteria may be enrolled into the study Willing and able to sign informed consent and complete the patient diary; Females age 8805;18 years; Patients with histologically or cytologically confirmed breast cancer BC , requiring Chemotherapy, who are na ve to chemotherapy; Scheduled to receive of a single dose of a MEC regimen on Day 1. Karnofsky Performance Status grade of 8805;60 see Appendix A ; Life-expectancy greater than 3 months; For women of child-bearing potential, negative serum or urine pregnancy test within 2 weeks of treatment and use of physician-approved method of birth control throughout the study; Acceptable hepatic function 8804;2 times the upper limit of normal ULN and renal function creatinine 8804;1.5 times ULN .
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Prior treatment with palonosetron; Known hypersensitivity reaction to any 5-HT3 receptor antagonists; Know hypersensitivity to dexamethasone; Prior treatment with chemotherapy; Scheduled receipt of MEC, radiotherapy, or HEC according to the Hesketh classification level 3 or higher on Days 2 to 6 see Appendix B ; Anti-emetic therapy within 24 hours of treatment initiation or scheduled receipt of up to Day 5 of any drug with antiemetic effects; Nausea or vomiting with an National Cancer Institute NCI Common Toxicity Symptomatic brain metastases; Gastric outlet or intestinal obstruction; Known current or history of drug or alcohol abuse; Participation in another study within 30 days of before or after study entry. Criteria CTC of grade 2 or 3 in the 24 hours before receiving study medication see Appendix C Ongoing vomiting from any other organic etiology Female patients who are pregnant or breast feeding History of seizures

研究者

相似试验

进行中(未招募)
不适用
Double-blind Study to Compare the Efficacy of Palonosetron with or without the use of Dexamethasone on Days 2 and 3, in the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy (MEC) Given to Female Patients with Breast Cancer - PALO 05-02This is a non-inferiority study in chemotherapy-naïve female patients with breast cancer, age 18 years or older, who are scheduled to receive Moderately Emetogenic Chemotherapy (MEC).
EUCTR2005-002643-89-ATHelsinn Healthcare SA300
进行中(未招募)
不适用
Double-blind Study to Compare the Efficacy of Palonosetron with or without the use of Dexamethasone on Days 2 and 3, in the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy (MEC) Given to Female Patients with Breast Cancer - PALO 05-02
EUCTR2005-002643-89-ESHelsinn Healthcare SA300
进行中(未招募)
不适用
Double-blind Study to Compare the Efficacy of Palonosetron with or without the use of Dexamethasone on Days 2 and 3, in the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy (MEC) Given to Female Patients with Breast Cancer - PALO 05-02
EUCTR2005-002643-89-DEHelsinn Healthcare SA300
已完成
4 期
A study to compare palonosetron with ondansetron for prevention of postoperative nausea vomiting (PONV) following gynaecological surgeries.
CTRI/2018/03/012655Rohit130
未知
3 期
Double-blind randomized study to compare the efficacy and safety of tamsulosin prolonged release tablet 0.4 mg with Harnal capsule 0.2 mg in patients with lower urinary tract symptoms (LUTS) associated with benign prostate hyperplasia (BPH)
JPRN-jRCT1080221287Astellas Pharma Inc.400